β catenin  (Proteintech)

Journal: International Dental Journal

Article Title: Meis1 Negatively Regulates Epithelial-Mesenchymal Transition via Wnt/β-catenin Pathway in Oral Submucous Fibrosis

doi: 10.1016/j.identj.2025.109323

Figure Lengend Snippet: Meis1 regulated EMT through the Wnt/β-catenin pathway. ( A ) q-PCR analysis of Meis1 knockdown efficiency in HaCaT cells transfected with sh-Meis1 plasmids, ** P < .01. ( B ) Western blot analysis of Meis1 knockdown efficiency in HaCaT cells transfected with sh-Meis1 plasmids. ( C ) Western blot analysis of lentivirus-mediated Meis1 knockdown efficiency by shRNA in HaCaT cells. ( D ) Venn diagram showing overlapping differentially expressed genes (DEGs) between the TGF-β1-induced group and sh-Meis1-2 group (C1: the control group; C2: TGF-β1-induced group; C3: sh-Meis1-2 group). ( E ) Pathway enrichment analysis of overlapping DEGs between the TGF-β1-induced group and sh-Meis1-2 group. ( F-H ) q-PCR analysis of β-catenin, cyclin D1, and c-Myc mRNA expression in cells with Meis1 overexpression, * P < .05, ** P < .01. ( I ) Western blot analysis of β-catenin, c-Jun, c-Myc, and cyclin D1 protein expression in cells with Meis1 overexpression. ( J-L ) q-PCR analysis of β-catenin, cyclin D1, and c-Myc mRNA expression in cells with Meis1 knockdown, * P < .05, ** P < .01. ( M ) Western blot analysis of β-catenin, c-Jun, c-Myc, and cyclin D1 protein expression in cells with Meis1 knockdown. ( N ) Western blot analysis of β-catenin protein expression in cells with or without MSAB treatment. ( O ) Western blot analysis of α-SMA, Vimentin, E-cadherin, and N-cadherin protein expression in cells with or without MSAB treatment.

Article Snippet: MSAB was used to treat HaCaT cells by blocking the Wnt/β-catenin pathway (MCE, HY-120697).

Techniques: Knockdown, Transfection, Western Blot, shRNA, Control, Expressing, Over Expression

Journal: Bioactive Materials

Article Title: Bacteria-responsive DNAgel system for targeted delivery of photothermally enhanced MXene/MoS 2 in the treatment of pyogenic osteomyelitis

doi: 10.1016/j.bioactmat.2025.10.023

Figure Lengend Snippet: MXMoS 2 activates Wnt signaling pathways to promote osteogenic differentiation and enhance bone regeneration. (A) GO pathway enrichment analysis of differentially expressed genes between the experimental and control groups. (B) KEGG pathway enrichment analysis of differentially expressed genes between the experimental and control groups. (C) Heatmap of inflammation-related gene expression. (D) GSEA of GO analysis in the experimental and control groups, demonstrating pathways such as osteoblast differentiation, regulation of macrophage activation, cell adhesion, positive regulation of cell migration,cell-cell junction. (E) PPI analyses identifying four distinct gene clusters (modules). (F) Bubble chart showed the various network topology metrics for the 4 modules weighted and quantified to obtain an overall score. (G) GO analysis of the genes in module 2 showed that they are associated with osteoblast differentiation and the Wnt signaling pathway. (H) Box plot of representative Wnt signaling pathway genes significantly upregulated in the MXMoS 2 group. (I) The six genes mentioned above were predicted for their upstream transcription factor regulation. (J) Schematic illustration of the mechanism of MXMoS 2 regulating macrophage polarization. (K) Representative Western blot images of WNT4 and β-Catenin expression in control group (LPS), MXMoS 2 group (LPS + MXMoS 2 ) and MXMoS 2 +siRNA group (LPS + MXMoS 2 +siRNA-WNT4). (L – M) Quantification of WNT4 and β-Catenin protein levels corresponding to (K) . ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.

Article Snippet: Primary antibodies for immunocytochemistry and immunofluorescence staining—including ARG1 and iNOS, TRAP, β-Catenin, OCN and WNT4—were obtained from Proteintech (China).

Techniques: Protein-Protein interactions, Control, Gene Expression, Activation Assay, Migration, Western Blot, Expressing

Journal: Cell Communication and Signaling : CCS

Article Title: Genetically engineered macrophages delivering TRAIL targeting the Wnt/β-catenin pathway to induce cytotoxicity against TNBC

doi: 10.1186/s12964-025-02394-7

Figure Lengend Snippet: Engineered macrophages delivering TRAIL inhibit Wnt/β-catenin-mediated cell cycle regulation to suppress TNBC growth in vitro. A and B . Flow cytometry analysis of the cell cycle in 4T1 cells treated with mouse Mono-TRAIL-M and Tri-TRAIL-M; C . Western blot analysis the protein expression of cyclin B1 and c-myc in 4T1 cells co-cultured with mouse Mono-TRAIL-M and Tri-TRAIL-M; D . Relative CTNNB1 mRNA expression in 4T1 cells co-cultured with mouse Mono-TRAIL-M and Tri-TRAIL-M; E . Western blot analysis the protein expression of β-catein, GSK3β, p-GSK3β; F . Immunofluorescence analysis of β-catenin nuclear localization; G . Western blot analysis of β-catenin, Cyclin B1, c-Myc, and C-caspase 3 expression in 4T1 cells treated with conditioned medium derived from Tri-TRAIL-M macrophages, with or without the pan-caspase inhibitor z-VAD-FMK

Article Snippet: Cells were incubated overnight at 4 °C with a primary antibody against β-catenin (Proteintech, 66379-1-Ig), followed by Alexa Fluor 488-conjugated secondary antibody (CST, 8878 S) for 1 h at room temperature.

Techniques: In Vitro, Flow Cytometry, Western Blot, Expressing, Cell Culture, Immunofluorescence, Derivative Assay

Journal: Cell Communication and Signaling : CCS

Article Title: Genetically engineered macrophages delivering TRAIL targeting the Wnt/β-catenin pathway to induce cytotoxicity against TNBC

doi: 10.1186/s12964-025-02394-7

Figure Lengend Snippet: Schematic diagram of genetically engineered macrophages delivering TRAIL targeting the Wnt/β-catenin pathway to enhance TNBC immunotherapy

Article Snippet: Cells were incubated overnight at 4 °C with a primary antibody against β-catenin (Proteintech, 66379-1-Ig), followed by Alexa Fluor 488-conjugated secondary antibody (CST, 8878 S) for 1 h at room temperature.

Techniques: